Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Clin Transl Oncol ; 21(12): 1583-1623, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30949930

RESUMO

Progresses in multimodal treatments have significantly improved the outcomes for childhood cancer. Nonetheless, for about one-third of patients with Ewing sarcoma, rhabdomyosarcoma, or osteosarcoma steady remission has remained intangible. Thus, new biomarkers to improve early diagnosis and the development of precision-targeted medicine remain imperative. Over the last decade, remarkable progress has been made in the basic understanding of miRNAs function and in interpreting the contribution of their dysregulation to cancer development and progression. On this basis, this review focuses on what has been learned about the pivotal roles of miRNAs in the regulation of key genes implicated in childhood sarcomas.


Assuntos
Neoplasias Ósseas/metabolismo , MicroRNAs/metabolismo , Osteossarcoma/metabolismo , Rabdomiossarcoma/metabolismo , Sarcoma de Ewing/metabolismo , Neoplasias Ósseas/genética , Criança , Regulação para Baixo , Humanos , Osteossarcoma/genética , Rabdomiossarcoma/genética , Sarcoma de Ewing/genética , Regulação para Cima
3.
Horm Metab Res ; 47(9): 656-61, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25985323

RESUMO

DAX1 transcription factor is a key determinant of adrenogonadal development, acting as a repressor of SF1 targets in steroidogenesis. It was recently demonstrated that DAX1 regulates pluripotency and differentiation in murine embryonic stem cells. In this study, we investigated DAX1 expression in adrenocortical tumors (ACTs) and correlated it with SF1 expression and clinical parameters. DAX1 and SF1 protein expression were assessed in 104 ACTs from 34 children (25 clinically benign and 9 malignant) and 70 adults (40 adenomas and 30 carcinomas). DAX1 gene expression was studied in 49 ACTs by quantitative real-time PCR. A strong DAX1 protein expression was demonstrated in 74% (25 out of 34) and 24% (17 out of 70) of pediatric and adult ACTs, respectively (χ(2)=10.1, p=0.002). In the pediatric group, ACTs with a strong DAX1 expression were diagnosed at earlier ages than ACTs with weak expression [median 1.2 (range, 0.5-4.5) vs. 2.2 (0.9-9.4), p=0.038]. DAX1 expression was not associated with functional status in ACTs. Interestingly, a positive correlation was observed between DAX1 and SF1 protein expression in both pediatric and adult ACTs (r=0.55 for each group separately; p<0.0001). In addition, DAX1 gene expression was significantly correlated with SF1 gene expression (p<0.0001, r=0.54). In conclusion, DAX1 strong protein expression was more frequent in pediatric than in adult ACTs. Additionally, DAX1 and SF1 expression positively correlated in ACTs, suggesting that these transcription factors might cooperate in adrenocortical tumorigenesis.


Assuntos
Neoplasias do Córtex Suprarrenal/metabolismo , Carcinogênese/metabolismo , Receptor Nuclear Órfão DAX-1/metabolismo , Fator Esteroidogênico 1/metabolismo , Neoplasias do Córtex Suprarrenal/genética , Adenoma Adrenocortical/genética , Adenoma Adrenocortical/metabolismo , Carcinoma Adrenocortical/genética , Carcinoma Adrenocortical/metabolismo , Adulto , Carcinogênese/genética , Criança , Pré-Escolar , Receptor Nuclear Órfão DAX-1/genética , Feminino , Expressão Gênica , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Fator Esteroidogênico 1/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...